Literature DB >> 8959349

Hepatocyte growth factor/scatter factor-Met signaling induces proliferation, migration, and morphogenesis of pancreatic oval cells.

M Jeffers1, M S Rao, S Rulong, J K Reddy, V Subbarao, E Hudson, G F Vande Woude, J H Resau.   

Abstract

Hepatocyte growth factor/scatter factor (HGF/SF) is a pleiotropic effector for cells expressing the Met tyrosine kinase receptor. In this investigation, we show that pancreatic oval cells express Met and exhibit a proliferative response to HGF/SF. Additionally, we found that oval cells treated transiently with this factor become "scattered," whereas those exposed to HGF/ SF for extended periods of time form branching tubular structures. These structures possess true lumens, which are lined by cells with ductal features, including apical microvilli, well-developed intercellular junctions, interdigitation of plasma membranes, and abundant cytoplasmic organelles. Interestingly, these ductal structures are formed by HGF/SF-treated cells cultured on plastic dishes in the absence of exogenous extracellular matrix components. Consistent with their ability to form ductal structures in vitro, we found that pancreatic oval cells form ductal adenocarcinomas in nude mice. This study supports the involvement of HGF/SF-Met signaling in the growth, migration, and morphogenesis of pancreatic oval cells and may have important implications for the expansion and morphogenic differentiation of these cells during developmental, regenerative, and neoplastic growth.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8959349

Source DB:  PubMed          Journal:  Cell Growth Differ        ISSN: 1044-9523


  12 in total

1.  Growth factor- and cytokine-driven pathways governing liver stemness and differentiation.

Authors:  Aránzazu Sánchez; Isabel Fabregat
Journal:  World J Gastroenterol       Date:  2010-11-07       Impact factor: 5.742

Review 2.  Pancreatic stem cells: differentiation options.

Authors:  M Sambasiva Rao; Janardan K Reddy
Journal:  Stem Cell Rev       Date:  2005       Impact factor: 5.739

3.  The role of the c-Met pathway in lung cancer and the potential for targeted therapy.

Authors:  Martin Sattler; Mamatha M Reddy; Rifat Hasina; Tara Gangadhar; Ravi Salgia
Journal:  Ther Adv Med Oncol       Date:  2011-07       Impact factor: 8.168

4.  Deletion of the Met tyrosine kinase in liver progenitor oval cells increases sensitivity to apoptosis in vitro.

Authors:  Gaelle del Castillo; Valentina M Factor; Margarita Fernández; Alberto Alvarez-Barrientos; Isabel Fabregat; Snorri S Thorgeirsson; Aránzazu Sánchez
Journal:  Am J Pathol       Date:  2008-04-01       Impact factor: 4.307

5.  Epidermal growth factor receptor plays a significant role in hepatocyte growth factor mediated biological responses in mammary epithelial cells.

Authors:  Alyssa R Bonine-Summers; Mary E Aakre; Kimberly A Brown; Carlos L Arteaga; Jennifer A Pietenpol; Harold L Moses; Nikki Cheng
Journal:  Cancer Biol Ther       Date:  2007-04       Impact factor: 4.742

6.  Current understanding of the molecular mechanisms of kidney cancer: a primer for urologists.

Authors:  Darwin L Lim; Raymond Ko; Stephen E Pautler
Journal:  Can Urol Assoc J       Date:  2007-06       Impact factor: 1.862

7.  Anti-apoptotic signaling by hepatocyte growth factor/Met via the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways.

Authors:  G H Xiao; M Jeffers; A Bellacosa; Y Mitsuuchi; G F Vande Woude ; J R Testa
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-02       Impact factor: 11.205

8.  The scaffolding protein GRASP/Tamalin directly binds to Dock180 as well as to cytohesins facilitating GTPase crosstalk in epithelial cell migration.

Authors:  Myriam A Attar; Lorraine C Santy
Journal:  BMC Cell Biol       Date:  2013-02-26       Impact factor: 4.241

9.  Paracrine effects of hepatocyte growth factor/scatter factor on non-small-cell lung carcinoma cell lines.

Authors:  S Yi; J R Chen; J Viallet; R H Schwall; T Nakamura; M S Tsao
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

10.  A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth.

Authors:  Douglas C Marchion; Elona Bicaku; Yin Xiong; Nadim Bou Zgheib; Entidhar Al Sawah; Xiaomang Ba Stickles; Patricia L Judson; Alex S Lopez; Christopher L Cubitt; Jesus Gonzalez-Bosquet; Robert M Wenham; Sachin M Apte; Anders Berglund; Johnathan M Lancaster
Journal:  Oncol Rep       Date:  2013-03-05       Impact factor: 3.906

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.